RxDoctor Payments Data

Michael Jerome, DO

Internal Medicine · Dallas, TXNPI 1306164967

Payments from drug & device makers

$735in general payments, 2019–2025

Across 32 payments — averaging $22.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$151
  • AstraZeneca$121
  • Boehringer Ingelheim$107
  • Novo Nordisk$60
  • Alk-abello, Inc$58
  • Amgen$55
  • plus $183 from 7 others

What the payments were for

  • Food & beverage$71697%
  • Education$193%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$735 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$23,296
Medicare patients
116
Services billed
232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate68$93,714
EliquisApixaban54$62,051
JardianceEmpagliflozin64$61,759
JanumetSitagliptin Phos/Metformin Hcl45$42,575
XareltoRivaroxaban18$21,595
FarxigaDapagliflozin Propanediol14$16,977
OzempicSemaglutide16$16,397
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog39$12,193
TrulicityDulaglutide12$11,201
Tresiba Flextouch U-100Insulin Degludec13$6,241
Breo ElliptaFluticasone/Vilanterol16$6,074
Rosuvastatin Calcium317$4,712
Novolog FlexpenInsulin Aspart20$4,379
Albuterol Sulfate HfaAlbuterol Sulfate133$3,658
Atorvastatin Calcium295$3,492

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$30$62,05154 claims
Boehringer IngelheimJardiance$107$61,75964 claims
AstraZenecaFarxiga$121$16,97714 claims
Novo NordiskOzempic$60$16,39716 claims
Lilly USA, LLCTrulicity$29$11,20112 claims
GSKBreo Ellipta$21$6,07416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →